Roberto AJ, Pires RNC, Leme AF, Bueno OG, Roberto AC

Language: Portugués
References: 7
Page: 199-201
PDF size: 382.56 Kb.

ABSTRACT

Therapy with inhibitors of tumor necrosis factor provide beneficial effects in various inflammatory immune diseases. We report the case of a man carrying Crohn’s disease six years ago and five years with severe psoriasis. He was elected for the use of infliximab, justified by the combination of two chronic inflammatory diseases. After 23 doses the patient is totally without skin lesions and satisfied with the improvement in quality of life and symptoms control of Crohn’s disease.

REFERENCES

1. Romiti R. Compêndio de psoríase. Editora Elsevier, Rio de Janeiro, 2010, p. 252.

2. Targa FC, Ferreira CT, Fernandes EI, Themis RS. Psoríase pustulosa associada à doença de Crohn: relato de caso. An Bras Dermatol, Rio de Janeiro. 2000; 75 (1): 57-64.

3. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor TNF- monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000; 42: 829-830.

4. Arruda L, Ypiranga S, Aires MG. Tratamento sistêmico da psoríase - Parte II: Imunomoduladores biológicos. An Bras Dermatol [online]. 2004; 79 (4): 393-408.

5. Rocha MAP, Gemio TM, Scanavini NA, Viera SFE, Correa ORL, Thierry R et al. Tratamento da doença de Crohn com infliximabe: primeira opção? ABCD, Arq Bras Cir Dig. 2009; 22 (2): 101-104.

6. Kawashima K, Ishihara S, Yamamoto A, Ohno Y, Fukuda K, Onishi K, Kinoshita Y. Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn’s disease. Inflamm Bowel Dis. 2012 Apr 16. doi: 10.1002/ibd.22922.

7. Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther. 2012; 35 (12): 1397-1407.